Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Beginning Cash Balance: 2012-2024

Historic Beginning Cash Balance for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $144.3 million.

  • Amphastar Pharmaceuticals' Beginning Cash Balance fell 1.02% to $187.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.1 million, marking a year-over-year decrease of 29.06%. This contributed to the annual value of $144.3 million for FY2024, which is 7.56% down from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Beginning Cash Balance stood at $144.3 million for FY2024, which was down 7.56% from $156.1 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Beginning Cash Balance registered a high of $156.1 million during FY2023, and its lowest value of $73.7 million during FY2020.
  • Its 3-year average for Beginning Cash Balance is $142.2 million, with a median of $144.3 million in 2024.
  • In the last 5 years, Amphastar Pharmaceuticals' Beginning Cash Balance fell by 14.65% in 2020 and then skyrocketed by 34.03% in 2022.
  • Amphastar Pharmaceuticals' Beginning Cash Balance (Yearly) stood at $73.7 million in 2020, then grew by 27.94% to $94.3 million in 2021, then skyrocketed by 34.03% to $126.4 million in 2022, then rose by 23.54% to $156.1 million in 2023, then dropped by 7.56% to $144.3 million in 2024.